FDA Places Hold on REGENXBIO’s RGX-111 and RGX-121 Trials After Tumor Case
The FDA has placed clinical holds on REGENXBIO’s RGX-111 and RGX-121 gene therapy trials after detecting an intraventricular CNS tumor in a 5-year-old MPS I patient four years post-treatment. No neoplasms have been reported in the other nine RGX-111 and 32 RGX-121 participants while the causality investigation continues.
1. Shares Plunge on Unusual Volume
REGENXBIO Inc. shares fell sharply on Wednesday as trading volume surged to 3.83 million shares, more than five times the 30-day average of 684,271. The abnormal activity coincided with news of an FDA clinical hold, prompting institutional and retail investors to liquidate positions. The heightened turnover suggests large block trades and stop-loss triggers, potentially exacerbating downward pressure on the stock and raising concerns about liquidity in the near term.
2. FDA Imposes Clinical Holds on RGX-111 and RGX-121
The U.S. Food and Drug Administration has placed a clinical hold on RGX-111 (MPS I) and RGX-121 (MPS II) gene therapy programs following the identification of an intraventricular CNS tumor in one asymptomatic five-year-old participant four years after intracisternal RGX-111 administration. Preliminary genetic analysis linked the tumor to an AAV vector integration event and overexpression of PLAG1. The FDA cited shared product characteristics and patient populations to justify holds on both programs, despite no neoplasms in the nine other RGX-111 or 32 RGX-121 subjects.
3. Ongoing Investigation and Regulatory Uncertainty
REGENXBIO has not yet received the full clinical hold letter and is awaiting detailed guidance from the FDA. The company’s internal investigation is assessing causality, but no definitive link between vector integration and malignancy has been established. Investors face uncertainty over the duration of the hold, potential protocol modifications, and the risk of further safety signals in long-term follow-up. Any extension of this hold could delay pivotal trial milestones and regulatory submissions, undermining the valuation of these late-stage assets.
4. Potential Impact on Pipeline Valuation and Partnerships
RGX-121 and RGX-111, both partners with Nippon Shinyaku, represented key drivers of future revenue, supported by Orphan Drug, Rare Pediatric Disease, Fast Track and RMAT designations. A protracted clinical hold threatens milestone payments under the collaboration agreements and could stall planned license expansions in Europe and Asia. With RGX-202 and NAVSUNLI still in early development, investors will closely monitor cash burn forecasts and potential capital raises. Management has signaled patient safety remains paramount but will need to reassure stakeholders on timelines and risk-mitigation strategies to stabilize the share price.